Combination therapy for advanced AFP-positive gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of chemotherapy (XELOX) plus two immunotherapy/targeted drugs (Sintilimab and Lenvatinib) in people with advanced stomach cancer that produces a high level of a protein called AFP. It aims to see if this combination is safe and can shrink tumors when given as the first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have advanced stomach cancer that has spread, is HER2-negative, and has an AFP blood level of 20 or higher.
- You have not received any previous treatment for advanced disease.
- Your tumors can be measured on scans.
- You are in good general health (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You can take pills by mouth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This clinical trial is testing a combination of three drugs—sintilimab, fruquintinib, and standard chemotherapy—as a first treatment for advanced stomach cancer that cannot be surgically removed. The goal is to see if this combination can shrink the cancer enough to allow surgery, potentially improving outcomes.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.